In addition, EGFR TKI treatment can induce epigenetic reprogramming in EGFR-mutant lung adenocarcinoma (LUAD), facilitating its transformation into SCLC through a process that involves transitional cell states (52). The gene discussed is EGFR; the disease is lung adenocarcinoma.